Methylone, 2C-B, And MBDB Reuptake Inhibitors for Self-Administration
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current psychoactive medications for neuropsychiatric disorders, such as MDMA and psilocybin, have limitations including safety concerns, drug-drug interactions, provider-intensive administration, and patient discomfort, limiting their effectiveness for treatment-resistant conditions like depression and PTSD.
Innovation Solution
Development of psychoactive compounds like methylone, 2C-B, and MBDB, which act as serotonin-norepinephrine-dopamine reuptake inhibitors, minimizing receptor agonism and antagonism, allowing for self-administration and reduced side effects, and offering rapid antidepressant and anxiolytic effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If classical psychedelics like MDMA and psilocybin are used for treating neuropsychiatric disorders, then therapeutic efficacy is improved, but safety concerns and drug-drug interactions worsen
Solution Approach 1:
The patent modifies the chemical structure of psychoactive compounds by changing molecular parameters - specifically using cathinone core structures with varied substituent groups (methylone, butylone, mephedrone, etc.) to alter pharmacological properties, reducing serotonin receptor agonism while maintaining therapeutic effects, thereby reducing safety concerns and drug interactions
Solution Approach 2:
The patent extracts and isolates specific active components from natural sources (such as cathinone from khat plant) and synthesizes purified analogs, removing harmful impurities and separating the therapeutic active principles from potentially harmful substances, thus improving safety profile while maintaining efficacy
2Reliability
If provider-intensive administration is used for psychoactive medicines, then safety monitoring is improved, but ease of operation and accessibility worsen
Solution Approach 1:
The patent develops formulations with improved pharmacokinetic properties (longer half-life, more stable plasma concentrations) that enable self-administration by patients, reducing the need for provider-intensive monitoring while maintaining safety through the compounds' inherent safety profile and reduced harmful effects
3Productivity
If conventional psychoactive medicines are used, then treatment effectiveness is improved, but patient discomfort and side effects worsen
Solution Approach 1:
The patent achieves selective pharmacological activity by modifying molecular structures to target specific receptors and pathways - using cathinone derivatives with varied substituents to selectively modulate dopamine, norepinephrine, and serotonin systems in a localized and controlled manner, thereby improving treatment effectiveness while reducing widespread side effects and patient discomfort
4Speed
If rapid-acting antidepressants are developed, then speed of action is improved, but reliability and safety profile worsen
Solution Approach 1:
The patent employs compounds with appropriate half-life characteristics that provide sustained therapeutic action through periodic release and metabolism, allowing rapid initial effect followed by maintained efficacy, thereby achieving fast-acting antidepressant properties while maintaining a reliable and safe profile through controlled duration of action
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These compounds provide a safer, more effective treatment for neuropsychiatric illnesses with fewer drug interactions, enabling faster-acting and more accessible therapy for conditions like depression, PTSD, and chronic pain, with minimal adverse effects.
Implementation Method 1
Development of psychoactive compounds like methylone, 2C-B, and MBDB, which act as serotonin-norepinephrine-dopamine reuptake inhibitors
Implementation Method 2
minimizing receptor agonism and antagonism
Implementation Method 3
Classical psychedelics are a class of mixed serotonergic-, noradrenergic-, and dopaminergic-modulating compounds
Data Source
AI summary
The invention relates to psychoactive medicines including methylone, 2C-B, MBDB, their respective salts, metabolites, isomers, enantiomers, solvates, isotopologues and isotopomers, polymorphs, prodrugs and analogs (2C-series and cathinones); their preparation, formulations, intermediates, routes of administration, dosing and schedule for medical uses for psychiatric and neurological conditions and disorders.